Huang B, Zhang Y, Ruan G, Yu X, Liu Q, Zhang M
J Cachexia Sarcopenia Muscle. 2024; 15(6):2693-2704.
PMID: 39474649
PMC: 11634476.
DOI: 10.1002/jcsm.13614.
Nagayama A, Inokuchi T, Ashida K, Inada C, Homma T, Miyazaki H
JMA J. 2024; 7(3):387-400.
PMID: 39114607
PMC: 11301034.
DOI: 10.31662/jmaj.2023-0214.
Naito A, Nagatomo Y, Kawai A, Yukino-Iwashita M, Nakazawa R, Taruoka A
J Pers Med. 2024; 14(2).
PMID: 38392575
PMC: 10890336.
DOI: 10.3390/jpm14020141.
Nakamura S, Sato Y, Kobayashi T, Oya A, Fujie A, Matsumoto M
Sci Rep. 2024; 14(1):2240.
PMID: 38279013
PMC: 10817916.
DOI: 10.1038/s41598-024-52689-x.
Kim H, Jung D, Williams D
Cells. 2023; 12(22).
PMID: 37998343
PMC: 10670210.
DOI: 10.3390/cells12222608.
Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment.
Salom Vendrell C, Garcia Tercero E, Moro Hernandez J, Cedeno-Veloz B
Nutrients. 2023; 15(19).
PMID: 37836433
PMC: 10574035.
DOI: 10.3390/nu15194149.
Current Nutritional and Pharmacological Approaches for Attenuating Sarcopenia.
Sakuma K, Hamada K, Yamaguchi A, Aoi W
Cells. 2023; 12(19).
PMID: 37830636
PMC: 10572610.
DOI: 10.3390/cells12192422.
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome.
Sano M
Int J Mol Sci. 2023; 24(6).
PMID: 36983057
PMC: 10057380.
DOI: 10.3390/ijms24065983.
Metabolic Impact of Frailty Changes Diabetes Trajectory.
Sinclair A, Abdelhafiz A
Metabolites. 2023; 13(2).
PMID: 36837914
PMC: 9960364.
DOI: 10.3390/metabo13020295.
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?.
Voorrips S, Saucedo-Orozco H, Sanchez-Aguilera P, de Boer R, van der Meer P, Westenbrink B
Int J Mol Sci. 2022; 23(15).
PMID: 35955784
PMC: 9369142.
DOI: 10.3390/ijms23158631.
Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype.
Sinclair A, Pennells D, Abdelhafiz A
Aging Clin Exp Res. 2022; 34(9):1949-1967.
PMID: 35723859
PMC: 9208348.
DOI: 10.1007/s40520-022-02142-8.
Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.
Otsuka H, Yokomizo H, Nakamura S, Izumi Y, Takahashi M, Obara S
Biochem J. 2022; 479(3):425-444.
PMID: 35048967
PMC: 8883489.
DOI: 10.1042/BCJ20210700.
Sarcopenia Is Associated With a Risk of Mortality in People With Type 2 Diabetes Mellitus.
Takahashi F, Hashimoto Y, Kaji A, Sakai R, Okamura T, Kitagawa N
Front Endocrinol (Lausanne). 2021; 12:783363.
PMID: 34858351
PMC: 8632440.
DOI: 10.3389/fendo.2021.783363.
Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice.
Bamba R, Okamura T, Hashimoto Y, Majima S, Senmaru T, Ushigome E
J Cachexia Sarcopenia Muscle. 2021; 13(1):574-588.
PMID: 34854254
PMC: 8818690.
DOI: 10.1002/jcsm.12814.
The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms.
Massimino E, Izzo A, Riccardi G, Della Pepa G
Cells. 2021; 10(8).
PMID: 34440727
PMC: 8393336.
DOI: 10.3390/cells10081958.
Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Tobita H, Yazaki T, Kataoka M, Kotani S, Oka A, Mishiro T
J Clin Biochem Nutr. 2021; 68(2):173-180.
PMID: 33879970
PMC: 8046003.
DOI: 10.3164/jcbn.20-129.
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2....
Yabe D, Shiki K, Suzaki K, Meinicke T, Kotobuki Y, Nishida K
BMJ Open. 2021; 11(4):e045844.
PMID: 33827843
PMC: 8031078.
DOI: 10.1136/bmjopen-2020-045844.
The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review.
Wu C, Tien K
J Diabetes Res. 2020; 2020:9368583.
PMID: 32695832
PMC: 7368208.
DOI: 10.1155/2020/9368583.
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D
J Diabetes Investig. 2020; 12(2):200-206.
PMID: 32623839
PMC: 7858125.
DOI: 10.1111/jdi.13340.
Myopathy secondary to empagliflozin therapy in type 2 diabetes.
Gao F, Hall S, Bach L
Endocrinol Diabetes Metab Case Rep. 2020; 2020.
PMID: 32478668
PMC: 7159254.
DOI: 10.1530/EDM-20-0017.
